LYRA, ready to move into Phase III with Significant Efficacy (p=0.03) in a $50 B market, 80 million patients in China alone. https://investors.lyratherapeutics.com/news-releases/news-release-details/lyra-therapeutics-announces-positive-outcome-end-phase-2-meeting Analyst: William Blair Focus Conference https://wsw.com/webcast/blair59/lyra/1950784